Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies - Archive ouverte HAL Access content directly
Journal Articles Future Medicinal Chemistry Year : 2022

Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies

(1, 2) , (1, 2) , (3) , (3) , (1) , (1) , (1) , (1) , (1) , (3) , (1)
1
2
3
Nemanja Djokovic
Dusan Ruzic
Katarina Nikolic

Abstract

Background: Post-translational modifications of histones constitute a dynamic process impacting gene expression. A well-studied modification is lysine methylation. Among the lysine histone methyltransferases, DOT1L is implicated in various diseases, making it a very interesting target for drug discovery. DOT1L has two substrates, the SAM cofactor that gives the methyl group and the lysine H3K79 substrate. Results: Using molecular docking, the authors explored new bisubstrate analogs to enlarge the chemical landscape of DOT1L inhibitors. The authors showed that quinazoline can successfully replace the adenine in the design of bisubstrate inhibitors of DOT1L, showing similar activity compared with the adenine derivative but with diminished cytotoxicity. Conclusion: The docking model is validated together with the use of quinazoline in the design of bisubstrate inhibitors.
Fichier principal
Vignette du fichier
FMC-2021-0251_HalPasteur.pdf (6.32 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

pasteur-03704094 , version 1 (24-06-2022)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

Corentin Bon, Magdalena Barbachowska, Nemanja Djokovic, Dusan Ruzic, Yang Si, et al.. Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies. Future Medicinal Chemistry, 2022, 14 (8), pp.557-570. ⟨10.4155/fmc-2021-0251⟩. ⟨pasteur-03704094⟩
21 View
65 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More